The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) standard of care abscess drainage. The primary endpoint is reduction in time to removal of the drainage catheter.

开始日期2025-12-01

申办/合作机构

University of Rochester

NCT06887036

/ Not yet recruiting临床2期IIT

Methylene Blue Treatment of Chronic Hepatitis B Virus Infection: a Pilot Study

HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease. Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. Patients with HBeAg-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. This treatment inhibits HBV reverse transcriptase and reduces viral replication, but does not affect HBsAg production. Treatment must be continued for life in most cases and is associated with high cumulative costs and the risk of development of resistance.
Recently, it has been shown that patients who show a decrease in their HBsAg levels are more likely to become HBsAg negative, seroconvert and be able to stop antiviral treatment, which is the ultimate goal of treatment, but unfortunately rarely achieved. Methylene blue (MB) has been shown to have an effect on HBsAg levels in vitro, making it a promising test for a new treatment for HBV.
This is an explorative pilot study, open label, dose-escalation, single center clinical trial on the efficacy of MB against HBV infection.
Primary objective is to assess the efficacy of incremental doses of MB against hepatitis B virus in patients with chronic hepatitis B assessed by the reduction of both the HBsAg and HBV DNA levels after 6 months of treatment and 6 months of follow-up.
Participant will be treated for 6 months with MB 100 mg capsules, and then followed up for a further 6 months. The initial dose of MB might be increased if the patient is a non-responder.

开始日期2025-05-01

申办/合作机构-

CTRI/2025/03/083028

/ Not yet recruiting临床3期

COMPARATIVE EVALUATION OF EFFICACY OF INDOCYANINE GREEN AND METHYLENE BLUE MEDIATED ANTIMICROBIAL PHOTODYNAMIC THERAPY AS AN ADJUNCT TO NON-SURGICAL TREATMENT OF PERIODONTITIS. A CLINICO-MICROBIAL STUDY - NIL

开始日期2025-04-01

申办/合作机构-

100 项与亚甲蓝相关的临床结果

登录后查看更多信息

100 项与亚甲蓝相关的转化医学

登录后查看更多信息

100 项与亚甲蓝相关的专利（医药）

登录后查看更多信息

73,753

项与亚甲蓝相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock

Article

作者: Heim, Christian ; Elbayomi, Mohamed ; Tandler, Rene ; Weyand, Michael ; Pathare, Presheet ; Kondruweit, Markus ; Dewald, Oliver

BACKGROUND:

Vasoplegic syndrome is associated with high mortality. Methylene blue (MB) is a guanylate cyclase inhibitor that ameliorates this re-distributive type of shock. This study aims to investigate the outcome in patients who received MB early postoperatively.

METHODS:

2753 patients who underwent cardiac surgery utilizing cardiopulmonary bypass at our institution in a time interval of two years were identified. The incidence of vasoplegic syndrome was 7.2% (n = 200). Pharmacy records identified 84 patients (group 1, MB group) who received methylene blue and 116 patients (group 2, Control group) who didn't receive the drug. This single-center retrospective cohort study's primary outcome was in-hospital mortality. Secondary outcomes were postoperative hemodialysis, serum lactate levels at 24 h postoperatively, and intensive care unit stay length in days.

RESULTS:

MB patients have a shorter ICU stay as compared to the control group (9 ± 8 days vs. 16 ± 6.9; p-value <.001). In the control group, postoperative hemodialysis was higher (20% in the MB group and 40% in the control group; p-value <.05). At 24 h post-op, the methylene blue group had reduced serum lactate levels (1.8 ± 1.2 vs. 4 ± 1.8 in the control group; p-value <.001). The methylene blue group had a decreased 24-hour norepinephrine dose (1.5 ± 1.2 vs. 2.8 ± 2 in the control group; p-value <.05). In-hospital mortality was not significantly different between the two groups (38% in the MB group vs. 43% in the control group).

CONCLUSION:

Early postoperative administration of methylene blue in patients with vasoplegic syndrome shortens intensive care unit stay and contributes to less end-organ damage.

2025-12-31·SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Enhancement of photocatalytic efficiency of copper oxide/zinc oxide-montmorillonite photocatalyst under visible light irradiation

Article

作者: Khaorapapong, Nithima ; Suppaso, Chomponoot ; Yamauchi, Yusuke ; Baoulan, Areebhorn ; Pongkan, Nipaporn ; Rattanawongsa, Wachiraya ; Asakura, Yusuke ; Intachai, Sonchai

The formation of copper oxide and zinc oxide mixture in montmorillonite was conducted by the reaction of an aqueous dispersion of Cu²⁺/Zn²⁺ exchanged montmorillonite and an aqueous solution of sodium hydroxide under hydrothermal treatment. The resulting product was characterized by X-ray diffraction, scanning and transmittance electron microscopies, as well as UV-visible and photoluminescence spectroscopies. The diffuse reflectance absorption spectra showed the absorption onsets due to copper oxide (885 nm) and zinc oxide (310 and 580 nm) in the product. The adsorption of methylene blue was fitted well by the Langmuir model with the maximum adsorption capacity of 454 mg⋅g^-1. The thermodynamic studies revealed that the process is exothermic and spontaneous. The photocatalytic activity of the hybrid was assessed by the degradation of methylene blue in aqueous solution under visible light irradiation. The most active species in the photocatalytic process was hydroxyl radicals. The regenerated copper oxide/zinc oxide-montmorillonite was reused up to 5 cycles, the photodegradation efficiency dropped only 5% (from 94% to 89%), supporting the good stability of the photocatalyst. The result was in agreement with the advantages of the nanocomposite heterostructure and the unique nature of montmorillonite.

2025-12-01·Techniques in Coloproctology

The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit

Article

作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G

BACKGROUND:

Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.

METHODS:

A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.

RESULTS:

Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.

CONCLUSION:

Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.

项与亚甲蓝相关的新闻（医药）

2025-05-06

·Business Wire

AgelessRx Launches Methylene Blue, Pioneering Accessible Cognitive Longevity Solutions

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a pioneer in longevity and telehealth solutions, announces the launch of its newest offering: Methylene Blue capsules. Recent studies suggest that Methylene Blue may support focus, brain health, and cellular energy production, all in a mess-free, convenient capsule format. The launch of Methylene Blue marks AgelessRx’s launch into the cognitive health market valued at $11.55 billion in 2025 and projected to reach $40.27 billion by 2035. The global Methylene Blue market is projected to grow at a 7.3% CAGR through 2032, demonstrating ongoing interest and demand in innovative, preventive health solutions. By introducing a precision-dosed, purely sourced, stain-free form factor, AgelessRx is expanding access to a promising compound with multiple potential benefits that research is continually uncovering. Methylene Blue marks the company’s third product unveiling in just under four months, demonstrating the brand's commitment to bringing next-generation longevity solutions to market. “Methylene Blue has stood the test of time, with over 150 years of therapeutic use and is considered one of the first synthetic drugs,” said Dr. Sajad Zalzala, Chief Medical Officer and Co-Founder of AgelessRx. “Today, it’s gaining new relevance as a potential tool for improving cognitive and cellular health. We're proud to help bring this powerful molecule into modern preventive care, further supporting our mission to make longevity accessible for all.” Research highlights Methylene Blue’s multifaceted potential benefits, including: Cognitive Support & Memory Enhancement: Boosting performance by improving memory, focus, and overall cognitive performance . Mitochondrial Energy Boost: Enhancing mitochondrial efficiency to increase ATP production, which may improve energy while reducing fatigue and brain fog. Anti-inflammatory Support: Stifling inflammatory pathways in the brain to reduce inflammation, which may enhance recovery and slow brain degeneration. Neuroprotection and Healthy Brain Aging: Slowing cognitive decline by improving mitochondrial function and boosting blood flow to the brain. “Cognitive health is central to quality of life as we age,” shared AgelessRx’s VP of Applied Sciences, Stefanie Morgan. “By targeting and remedying the major hallmarks of brain aging, recent studies suggest that this new offering may represent an important step to mitigate the effects of cognitive decline as we age.” By offering Methylene Blue in a unique capsulated form, users will benefit from stain-free consumption alongside clinically guided protocols for more precise and personalized dosing supported by expert-led longevity clinicians. As the demand for proactive cognitive care grows, AgelessRx remains committed to delivering clinically validated, science-backed solutions that help millions live better, healthier lives. For additional information about AgelessRx and its newest offering, Methylene Blue, please visit agelessrx.com. About AgelessRx AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, Facebook, and LinkedIn.

2025-04-21

·PRNewswire

Shed Expands Longevity Product Line with Launch of Methylene Blue and Sermorelin

New offerings deliver science-backed support for energy, cognitive function, and healthy aging. SALT LAKE CITY, April 21, 2025 /PRNewswire/ -- Shed, a leader in personalized wellness, is proud to announce the expansion of its longevity category with the introduction of two advanced peptide-based products: Methylene Blue and Sermorelin. These additions reinforce Shed's position at the forefront of the longevity and wellness movement - providing clients with trusted, effective tools to take charge of their health journey. Continue Reading Shed now offering Methylene Blue and Sermorelin in longevity category. "At Shed, our mission has always been to empower individuals on their wellness journey with products that are not only effective, but rooted in real science," said Morley Baker, CEO of Shed. "With the addition of Methylene Blue and Sermorelin, we're addressing key aspects of longevity and performance through evidence-based innovation." Methylene Blue: Cognitive Enhancement & Cellular Energy Support Methylene Blue is a potent nootropic that enhances mitochondrial function, the energy engines of the body's cells. By supporting cellular energy production and acting as a powerful antioxidant and anti-inflammatory, Methylene Blue has shown potential benefits in: Increasing energy and mental clarity Enhancing memory, mood, and cognitive performance Reducing oxidative stress and slowing signs of aging Sermorelin: Restoring Vitality Through Natural Hormonal Support Sermorelin is a synthetic analog of the body's natural growth hormone-releasing hormone (GHRH). By stimulating the pituitary gland to increase natural HGH production, Sermorelin offers broad health benefits, including: Improved exercise recovery and performance Increased muscle mass and fat metabolism Enhanced bone density and cardiovascular health Better sleep, skin elasticity, libido, and immune function Often used in anti-aging and performance protocols, Sermorelin helps the body restore what time has taken, supporting greater vitality and resilience. "This is just the beginning," added Baker. "We're continuing to innovate with wellness tools that are deeply personal, rigorously tested, and designed to help you be the real you." Find out more about Shed's full longevity offering here. About Shed Shed is on a mission to redefine wellness with modern, personalized treatments designed to help people feel better from the inside out. Whether it's supporting longevity, boosting energy, or managing weight, Shed delivers convenient and affordable solutions that fit real lives, putting better health within reach for all. Media Contact: Jamie Neider 801-520-5785 [email protected] SOURCE Shed WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-04-07

·信狐药迅

北京永泰首款实体瘤细胞治疗爱可仑赛注射液提交上市申请|新受理（3.31-4.6）

本周药品注册受理数据，分门别类呈现，一目了然。(3.31-4.6）新药上市申请药品名称企业注册分类受理号爱可仑赛注射液北京永泰生物制品有限公司1CXSS2500039新药临床申请药品名称企业注册分类受理号VCT220片苏州闻泰医药科技有限公司1CXHL2500355VCT220片苏州闻泰医药科技有限公司1CXHL2500354VCT220片苏州闻泰医药科技有限公司1CXHL2500353JMKX005425片上海济煜医药科技有限公司1CXHL2500352SHR2554片江苏恒瑞医药股份有限公司1CXHL2500347SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500346SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500345SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500344枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500351枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500350枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500349枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500348自复制RNA带状疱疹疫苗嘉晨西海(杭州)生物技术有限公司1.2CXSL2500259Cizutamig注射液上海坦蒂生物医药科技有限公司1CXSL2500265ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500264LM-168注射液礼新医药科技(上海)有限公司1CXSL2500260ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500263MRG007乐普生物科技股份有限公司1CXSL2500262IMC-003宜明凯尔生物医药技术(上海)有限公司1CXSL2500261注射用SHR-A1904苏州盛迪亚生物医药有限公司1CXSL2500258注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500256重组抗CD19m-CD3抗体注射液天劢源和生物医药(上海)有限公司1CXSL2500255注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500254SHR-1701注射液苏州盛迪亚生物医药有限公司1CXSL2500253阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500257仿制药申请药品名称企业注册分类受理号二羟丙茶碱注射液山东益健药业有限公司3CYHS2501299乙酰半胱氨酸片海南赛立克药业有限公司3CYHS2501292氯化钙注射液武汉市小铂生物科技有限公司3CYHS2501282吲哚布芬片郑州韩都药业集团有限公司3CYHS2501281维生素B6注射液扬州中宝药业股份有限公司3CYHS2501245右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501242右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501241托伐普坦口腔崩解片浙江和泽医药科技股份有限公司3CYHS2501277乙酰半胱氨酸注射液广东君康药业有限公司3CYHS2501276富马酸酮替芬口服溶液江苏润恒制药有限公司3CYHS2501275维生素B6注射液江苏悦兴医药技术有限公司3CYHS2501255盐酸溴己新口服溶液湖北海美纳医药科技有限公司3CYHS2501253复合磷酸氢钾注射液安徽双鹤药业有限责任公司3CYHS2501270依巴斯汀口服溶液江西心正药业有限责任公司3CYHS2501258硫代硫酸钠注射液江苏九旭药业有限公司3CYHS2501257泛昔洛韦片浙江车头制药股份有限公司3CYHS2501240泛昔洛韦片浙江车头制药股份有限公司3CYHS2501239注射用硫酸多黏菌素B福安药业集团烟台只楚药业有限公司3CYHS2501237氟哌啶醇口服溶液上海理想制药有限公司3CYHS2501233盐酸戊乙奎醚注射液国药集团工业有限公司廊坊分公司4CYHS2501254阿那曲唑片海南日中天制药有限公司4CYHS2501251布瑞哌唑片昆山龙灯瑞迪制药有限公司4CYHS2501248玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501298玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501297钆特酸葡胺注射液广州康臣药业有限公司4CYHS2501296甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501295甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501294复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501293复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501291碳酸镧咀嚼片浙江仟源海力生制药有限公司4CYHS2501290长链脂肪乳注射液(OO)江苏盈科生物制药有限公司4CYHS2501289低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501288低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501287低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501286低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501285低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501284低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501283夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501246来特莫韦注射液苏州第壹制药有限公司4CYHS2501244妥布霉素滴眼液润尔眼科药物(广州)有限公司4CYHS2501243枸橼酸钠血滤置换液山东齐都药业有限公司4CYHS2501280盐酸伐地那非片江西施美药业股份有限公司4CYHS2501279盐酸伐地那非片江西施美药业股份有限公司4CYHS2501278艾拉莫德片山东现代医药科技有限公司4CYHS2501274米库氯铵注射液中玉制药(海口)有限公司4CYHS2501273复方氨基酸注射液(18AA-VII)湖北长联杜勒制药有限公司4CYHS2501272双氯芬酸钠缓释片江苏万高药业股份有限公司4CYHS2501252乳果糖口服溶液大玮(安徽)药业有限公司4CYHS2501271西甲硅油乳剂南通广承制药有限公司4CYHS2501250腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501269蛋白琥珀酸铁口服溶液海南康成药业有限公司4CYHS2501249腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501268夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501247腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501267腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501266腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501265腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501264他达拉非片国大(吉林)制药集团有限公司4CYHS2501263他达拉非片国大(吉林)制药集团有限公司4CYHS2501262他达拉非片国大(吉林)制药集团有限公司4CYHS2501261注射用头孢他啶阿维巴坦钠山东致泰医药技术有限公司4CYHS2501260枸橼酸托法替布缓释片南京易亨制药有限公司4CYHS2501259非奈利酮片杨凌科森生物制药有限责任公司4CYHS2501256阿达帕林凝胶珠海市汇通达医药有限公司4CYHS2501238盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501236盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501235亚甲蓝肠溶缓释片南京正大天晴制药有限公司4CYHS2501234司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500043司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500042司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500041司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500040西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005进口申请药品名称企业注册分类受理号Clesrovimab注射液Merck Sharp & Dohme B.V.1JXSS2500042本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500040本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500039注射用德曲妥珠单抗Daiichi Sankyo Europe GmbH3.1JXSS2500041磷霉素氨丁三醇颗粒LABIANA Pharmaceuticals, S.L.U.5.2JYHS2500016氯巴占口服混悬液MARTINDALE PHARMACEUTICALS LIMITED5.2JYHS2500017Bimagrumab注射液Eli Lilly and Company1JXSL2500050Bimagrumab注射液Eli Lilly and Company1JXSL2500049Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500052Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500051注射用佐妥昔单抗Astellas Pharma Global Development,Inc.2.2JXSL2500048中药相关申请药品名称企业注册分类受理号芪桂络痹通片北京以岭药业有限公司1.1CXZS2500014二冬汤颗粒浙江维康药业股份有限公司3.1CXZS2500013西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗细胞疗法ASH会议临床申请

100 项与亚甲蓝相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02312	亚甲蓝	V04CG05 V03AB17	DB09241

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结直肠癌	中国	Alfasigma SpA	2024-06-11
结直肠癌	中国	深圳市康哲药业有限公司	2024-06-11
高铁血红蛋白血症	欧盟	Provepharm SAS	2011-05-06
高铁血红蛋白血症	冰岛	Provepharm SAS	2011-05-06
高铁血红蛋白血症	列支敦士登	Provepharm SAS	2011-05-06
高铁血红蛋白血症	挪威	Provepharm SAS	2011-05-06
细菌感染	-	-	2011-01-01
中毒	中国	济川药业集团有限公司	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
可见病灶	申请上市	加拿大	PharmaSciences, Inc.	2021-12-22
胃肠道疾病	临床3期	美国	Cosmo Pharmaceuticals NV	-
脓毒性休克	临床2期	美国	Provepharm Life Solutions SA	2019-12-01
结肠疾病	临床2期	-	Cosmo Technologies Ltd.	2011-05-02
阿尔茨海默症	临床2期	-	TauRx Therapeutics Ltd.	2004-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06284941 (CTgov)	N/A	镇痛	90	ropivacaine (0.25% Ropivacaine 30ml for Iliac Fascia Block)	觸鏇鹹淵艱鹹範願鹽壓(醖顧艱糧選網鬱構窪醖) = 網齋網憲鬱觸艱廠範蓋獵蓋獵憲壓製窪積壓壓 (憲積遞衊築獵鹽糧餘願, 鹽築鏇鹽繭範餘齋襯繭 ~ 膚艱憲範餘鹹窪築網遞) 更多	-	2025-02-04
				Ropivacaine combined+methylene blue for iliac fascia block (0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block)	觸鏇鹹淵艱鹹範願鹽壓(醖顧艱糧選網鬱構窪醖) = 窪選淵艱餘願糧齋艱蓋獵蓋獵憲壓製窪積壓壓 (憲積遞衊築獵鹽糧餘願, 窪獵顧獵廠淵鹽遞鹽構 ~ 齋製襯艱範艱簾選廠襯) 更多
NCT06005558 (Pubmed \| BMC Anesthesiol)	临床2/3期	-	90	Placebo	憲糧願蓋淵構網築壓衊(艱遞鏇窪選壓襯齋鹹醖): HR = 0.29 (95% CI, 0.09 ~ 0.9)	积极	2025-01-08
				Methylene Blue 4 mg/kg
NCT04187053 (CTgov)	临床4期	炎症 \| Dent病 \| 种植体周围炎	56	Conventional mechanical therapy+Methylene Blue (Conventional Mechanical Therapy With aPDT Adjunct)	構鑰繭憲襯製蓋選憲壓(獵簾築齋鏇艱壓選膚廠) = 簾衊襯構積襯齋窪憲鬱選簾獵膚鹽簾餘構鹽鹹 (構選淵窪獵遞膚鹹衊蓋, 0.49) 更多	-	2023-12-29
				Conventional mechanical therapy+Saline (Conventional Mechanical Therapy With Sham aPDT Treatment)	構鑰繭憲襯製蓋選憲壓(獵簾築齋鏇艱壓選膚廠) = 鏇淵窪願膚築蓋鏇網範選簾獵膚鹽簾餘構鹽鹹 (構選淵窪獵遞膚鹹衊蓋, 0.70) 更多
EADV2023	N/A	甲癣	-	2% w/w aqueous solution of MB	襯齋餘網鹽鑰簾鑰積鏇(構窪衊顧遞餘觸糧範鑰) = 廠窪鏇顧衊蓋鏇觸築築築膚網觸製顧鏇襯積鹽 (糧築齋襯衊鑰艱窪獵鏇 ) 更多	积极	2023-10-11
				topical ungual cream with 40% w/w of urea and 2% w/w of MB	襯齋餘網鹽鑰簾鑰積鏇(構窪衊顧遞餘觸糧範鑰) = 築範糧築餘願積願壓襯築膚網觸製顧鏇襯積鹽 (糧築齋襯衊鑰艱窪獵鏇 ) 更多
ATS2023	N/A	休克	-	Methylene Blue	觸憲齋鹹鏇艱壓繭獵鑰(範繭築遞範膚齋糧顧顧) = Our patient survived and did not need prolonged ICU care or complications from MB 夢獵觸衊鏇廠淵鬱膚鹽 (淵憲網願蓋願齋廠構鏇 ) 更多	-	2023-05-21
NCT03395223 (MEBIPAM, CTgov)	临床4期	获得性高铁血红蛋白血症	7	Methylene Blue	觸襯範製顧獵衊選膚淵 = 膚夢鬱積積醖糧遞憲憲簾壓蓋顧積網繭糧膚艱 (選繭簾簾襯願醖顧範繭, 夢顧構鏇範廠鹹願築衊 ~ 膚憲選艱獵繭獵繭壓壓) 更多	-	2023-04-10
NCT04446871 (Pubmed \| Crit Care)	临床2/3期	脓毒性休克	91	Methylene blue	製顧醖鬱築淵網齋鑰壓(顧築築夢糧餘製簾選獵) = 膚繭艱鑰構憲範壓顧繭繭艱廠夢觸遞築衊鑰壓 (鹽醖遞築鑰蓋網網鑰鹹 )	-	2023-03-13
CRD42021281847 (Pubmed \| Front Med (Lausanne))	N/A	休克	832	Methylene Blue + Vasopressors	願衊鏇築顧觸餘鬱廠鏇(艱膚簾淵願範製觸網觸): OR = 0.54 (95% CI, 0.34 ~ 0.85), P-Value = 0.008 更多	积极	2022-09-26
				Control (no Methylene Blue)
EADV2022	N/A	甲癣	20	Fractional Er:YAG laser	繭鹽鬱淵選築壓選鏇衊(廠鹹鬱膚膚憲憲鬱網鹽) = 壓構繭糧壓繭醖獵製範醖淵廠蓋憲壓遞膚蓋獵 (鑰製廠鏇艱積衊願醖遞 )	积极	2022-09-07
NCT01386879 (CTgov)	临床4期	-	50	methylene blue (TaperGuard Evac ETT)	膚選衊鏇觸網廠顧網願 = 壓積遞鬱餘餘衊範繭壓齋構醖繭膚壓齋鹹鹹廠 (製鹹餘鬱醖蓋網艱鑰積, 糧網窪膚簾顧夢簾簾醖 ~ 齋願製膚壓膚淵壓遞壓) 更多	-	2022-06-08
				methylene blue (Teleflex ISIS ETT)	膚選衊鏇觸網廠顧網願 = 繭構襯憲觸餘網鹹構鬱齋構醖繭膚壓齋鹹鹹廠 (製鹹餘鬱醖蓋網艱鑰積, 鏇憲淵獵顧淵鹹繭鏇鏇 ~ 範襯蓋積簾齋壓遞構醖) 更多